93 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Article Searches
3 Medical Instruments Stocks to Buy Amid Improving Industry Trends https://www.zacks.com/commentary/2255364/3-medical-instruments-stocks-to-buy-amid-improving-industry-trends?cid=CS-ZC-FT-industry_outlook-2255364 Apr 15, 2024 - The Zacks Medical - Instruments industry is expected to gain from the rising adoption of smart healthcare options, including genAI. However, supply issues and staffing shortages continue to disrupt growth. EW, DXCM and STE appear well-poised to brave the challenges.
Tenet (THC) Divests Six Hospitals, Sustains Divestiture Spree https://www.zacks.com/stock/news/2249369/tenet-thc-divests-six-hospitals-sustains-divestiture-spree?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2249369 Apr 02, 2024 - Tenet Healthcare (THC) completes the sale of six California hospitals, four to UCI Health and two to Adventist Health, to refine the portfolio and reduce debt burden.
DexCom (DXCM) Upgraded to Buy: What Does It Mean for the Stock? https://www.zacks.com/stock/news/2248016/dexcom-dxcm-upgraded-to-buy-what-does-it-mean-for-the-stock?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_12_zacks_rank_upgrade-2248016 Mar 29, 2024 - DexCom (DXCM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Has DexCom (DXCM) Outpaced Other Medical Stocks This Year? https://www.zacks.com/stock/news/2246003/has-dexcom-dxcm-outpaced-other-medical-stocks-this-year?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_1-2246003 Mar 26, 2024 - Here is how DexCom (DXCM) and Anika Therapeutics (ANIK) have performed compared to their sector so far this year.
Reasons to Retain DexCom (DXCM) Stock in Your Portfolio for Now https://www.zacks.com/stock/news/2242241/reasons-to-retain-dexcom-dxcm-stock-in-your-portfolio-for-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2242241 Mar 18, 2024 - DexCom (DXCM) continues to raise optimism among investors, owing to its strong product portfolio.
Buy 5 Medical Devices Stocks for a Stable Portfolio in 2024 https://www.zacks.com/stock/news/2240686/buy-5-medical-devices-stocks-for-a-stable-portfolio-in-2024?cid=CS-ZC-FT-analyst_blog|investment_ideas-2240686 Mar 14, 2024 - We have narrowed our search to five Medical Instruments stocks with strong potential for 2024. These are: AORT, TMDX, DXCM, SWAV, EW.
Community Health (CYH), Cost Plus Drugs Unite to Lower Drug Cost https://www.zacks.com/stock/news/2237878/community-health-cyh-cost-plus-drugs-unite-to-lower-drug-cost?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2237878 Mar 08, 2024 - Community Health (CYH) collaborates with Cost Plus Drug to reduce drug costs and shortages.
DaVita (DVA) Expands Operational Footprint Via New Agreement https://www.zacks.com/stock/news/2236716/davita-dva-expands-operational-footprint-via-new-agreement?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2236716 Mar 06, 2024 - DaVita's (DVA) latest agreement is expected to serve a wider patient pool across Latin America.
DexCom (DXCM) Rises As Market Takes a Dip: Key Facts https://www.zacks.com/stock/news/2235686/dexcom-dxcm-rises-as-market-takes-a-dip-key-facts?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v2-2235686 Mar 04, 2024 - In the most recent trading session, DexCom (DXCM) closed at $122.30, indicating a +0.46% shift from the previous trading day.
ClearPoint Neuro (CLPT) Gets FDA's Nod for New Software https://www.zacks.com/stock/news/2231836/clearpoint-neuro-clpt-gets-fda-s-nod-for-new-software?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2231836 Feb 26, 2024 - ClearPoint Neuro's (CLPT) receipt of the FDA's latest approval is likely to provide fast, peri-procedural segmentation of the cortical structures of the brain.

Pages: 123456...10

Page 1>